CN114642262A - 抗幽益生菌组合物及其制品和制造方法 - Google Patents
抗幽益生菌组合物及其制品和制造方法 Download PDFInfo
- Publication number
- CN114642262A CN114642262A CN202210270282.1A CN202210270282A CN114642262A CN 114642262 A CN114642262 A CN 114642262A CN 202210270282 A CN202210270282 A CN 202210270282A CN 114642262 A CN114642262 A CN 114642262A
- Authority
- CN
- China
- Prior art keywords
- probiotic
- powder
- ghost
- probiotic powder
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 158
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 158
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 154
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title description 2
- 239000000843 powder Substances 0.000 claims abstract description 153
- 229920001202 Inulin Polymers 0.000 claims abstract description 16
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 16
- 229940029339 inulin Drugs 0.000 claims abstract description 16
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 14
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 14
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 10
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 10
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 10
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 9
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 5
- 210000002969 egg yolk Anatomy 0.000 claims description 37
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 26
- 241000894006 Bacteria Species 0.000 claims description 23
- 102000002322 Egg Proteins Human genes 0.000 claims description 22
- 108010000912 Egg Proteins Proteins 0.000 claims description 22
- 235000013345 egg yolk Nutrition 0.000 claims description 22
- 102000006395 Globulins Human genes 0.000 claims description 19
- 108010044091 Globulins Proteins 0.000 claims description 19
- 108060003951 Immunoglobulin Proteins 0.000 claims description 19
- 102000018358 immunoglobulin Human genes 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 14
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 6
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940037467 helicobacter pylori Drugs 0.000 abstract description 13
- 241000590002 Helicobacter pylori Species 0.000 abstract description 12
- 241000186000 Bifidobacterium Species 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 6
- 235000013361 beverage Nutrition 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 235000013948 strawberry juice Nutrition 0.000 description 6
- 206010019375 Helicobacter infections Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000219173 Carica Species 0.000 description 2
- 235000009467 Carica papaya Nutrition 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 description 2
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了抗幽益生菌组合物及其制品和制造方法,涉及食品用益生菌技术领域,抗幽益生菌组合物包括益生菌粉A、益生菌粉B、菊粉和低聚果糖,所述益生菌粉A包含动物双歧杆菌,所述益生菌粉B包含嗜酸乳杆菌或罗伊氏乳杆菌,所述益生菌粉A和所述益生菌粉B的重量比为1~3:1。本发明的抗幽益生菌组合物可用于食品、饮料和保健品的制造,能够解决现有技术中的幽门螺旋杆菌临床治疗依赖于多种药物联用,不能被有效抑制和预防且现有方法适用人群有限等技术问题。
Description
技术领域
本发明涉及食品用益生菌技术领域,具体涉及抗幽益生菌组合物及其制品和制造方法。
背景技术
幽门螺旋杆菌感染是引起一系列上消化道疾病的危险因素,患者感染幽门螺旋杆菌危害是很大的,容易导致上消化道疾病,包括慢性胃炎、消化性溃疡、胃癌或者胃淋巴瘤等。幽门螺杆菌是一种寄生于胃窦,对胃黏膜有损害的细菌,这种细菌的生命力旺盛,需要联合使用药物才能将其根治,目前临床上用来根治这种细菌的药物联合的方法,又称作为三联或四联疗法,这也表明使用抗生素治疗容易使得细菌产生耐药性,此外,由于生活习惯和环境因素,幽门螺旋杆菌感染仍可能多次复发。
幽门螺旋杆菌感染的三联或四联疗法甚至五联疗法不仅有副作用,由于不宜长期服用药物,不能对幽门螺杆菌产生长期的抑制和预防效果,多次用药治疗还会因细菌耐药性而导致药效下降;此外,因为众所周知的原因,抗生素的使用也是不被提倡的,而且抗生素尤其不适合被用于儿童或老人。在此背景下,寻求新的对抗幽门螺旋杆菌的保健型方法显得尤为必要。
发明内容
针对现有技术中的幽门螺旋杆菌临床治疗依赖于多种药物联用,不能被有效抑制和预防且现有方法适用人群有限等技术问题,本发明提供了抗幽益生菌组合物及其制品和制造方法,该抗幽益生菌组合物能够有效抑制和预防幽门螺旋杆菌感染,缓解胃部不适,避免了药物的副作用,更加安全。
为解决上述技术问题,本发明提供的技术方案为:抗幽益生菌组合物,包括益生菌粉A、益生菌粉B、菊粉和低聚果糖,所述益生菌粉A包含动物双歧杆菌,所述益生菌粉B包含嗜酸乳杆菌或罗伊氏乳杆菌,所述益生菌粉A和所述益生菌粉B的重量比为1~3:1。
可选地,所述益生菌粉A和所述益生菌粉B的活菌数量比为1~3:1。
可选地,还包括有蛋黄球蛋白粉或卵黄免疫球蛋白。
可选地,还包括果蔬粉,所述果蔬粉的重量大于所述蛋黄球蛋白粉或所述卵黄免疫球蛋白的重量。
可选地,所述蛋黄球蛋白粉或所述卵黄免疫球蛋白的重量大于或等于50mg。
可选地,所述抗幽益生菌组合物为粉末状混合物。
本发明还提供一种保健制品,包含所述的抗幽益生菌组合物。
本发明还提供一种抗幽益生菌组合物的制造方法,用于制造所述的抗幽益生菌组合物,对辅料进行干燥处理,将益生菌粉A和益生菌粉B置于车间内回温4~8小时,在干燥后的辅料中加入益生菌粉A和益生菌粉B进行混合,车间温度为18~23摄氏度,车间的相对湿度低于30%。
可选地,先将辅料与蛋黄球蛋白粉或卵黄免疫球蛋白混合10分钟以上;再加入益生菌粉A和益生菌粉B进行混合30分钟以上。
可选地,所述辅料包括菊粉、低聚果糖和果蔬粉。
可选地,所述辅料干燥至水分活性值为2.0~2.5,然后对干燥后的辅料进行称重操作。
采用本发明提供的技术方案,与现有技术相比,具有如下有益效果:
(1)通过改进益生菌配伍,该益生菌组合物可用于缓解胃部不适、腹泻、便秘,改善肠道菌群,减轻胃炎,使胃部环境不适于幽门螺杆菌生存,促使幽门螺杆菌从人体排出,减少幽门螺杆菌的定植,减轻抗生素用药带来的不良影响;
(2)采用菊粉和低聚果糖以促进双歧杆菌繁殖,帮助该益生菌组合物在体内产生更大效果,采用嗜酸乳杆菌或罗伊氏乳杆菌以对抗胃酸影响,增强该益生菌组合物的效果持续性;
(3)添加果蔬粉以改善口感和产品色泽,改善服用体验和拓展应用范围,可用于配制多种保健制品,例如固体饮料、保健食品和保健饮品;
(4)蛋黄球蛋白粉或卵黄免疫球蛋白与益生菌形成协同作用,有效抑制幽门螺杆菌,抑菌率或转阴率大于90%,降低幽门螺旋杆菌感染率,在不使用抗生素的情况下,增强人体免疫力,既可消除幽门螺旋杆菌又可在一定程度上预防再感染;
(5)所采用的动物双歧杆菌bb-12和嗜酸乳杆菌ncfm研究充分,适用人群更广,能够适用于老人与儿童,包括1岁以上的婴幼儿。
为使本发明的上述目的、特征和优点能更易于理解,提供部分较佳实施例,作详细说明如下。
具体实施方式
下面详细描述本发明的实施例,并不局限于所述最佳实施方式,不对本发明的内容和保护范围构成限制,任何人在本发明的启示下或是将本发明与其他现有技术的特征进行组合而得出的任何与本发明相同或相近似的产品,均落在本发明的保护范围之内。本发明中范围的公开包括在整个范围内的所有值和进一步细分范围的公开,包括对这些范围给出的端点和子范围。
本发明实施例公开了一种抗幽益生菌组合物,包括益生菌粉A、益生菌粉B、菊粉和低聚果糖,所述益生菌粉A包含动物双歧杆菌,动物双歧杆菌的菌株优选为Bb-12,所述益生菌粉B包含嗜酸乳杆菌或罗伊氏乳杆菌,嗜酸乳杆菌的菌株优选为NCFM,所述益生菌粉A和所述益生菌粉B的重量比为1~3:1。所述益生菌粉A和所述益生菌粉B的活菌数量比为1~3:1。该抗幽益生菌组合物还包括有蛋黄球蛋白粉或卵黄免疫球蛋白,所述蛋黄球蛋白粉或所述卵黄免疫球蛋白的重量大于或等于50mg。优选地,所述抗幽益生菌组合物为粉末状混合物。所述卵黄免疫球蛋白优选为禽类卵黄免疫球蛋白,更优选地为鸡卵黄免疫球蛋白。
该抗幽益生菌组合物还包括果蔬粉,所述果蔬粉的重量大于所述蛋黄球蛋白粉或所述卵黄免疫球蛋白的重量。
实施例1
本实施例提供一种抗幽益生菌组合物,包括1克益生菌粉A、1克益生菌粉B、1~2克菊粉和0.5~2克低聚果糖,所述益生菌粉A包含动物双歧杆菌,所述益生菌粉B包含嗜酸乳杆菌,益生菌粉A和益生菌粉B的活菌数量均为50亿。该抗幽益生菌组合物还包括有50mg蛋黄球蛋白粉。该抗幽益生菌组合物为粉末状混合物。
作为保健品原料时,该抗幽益生菌组合物还包括0.5克果蔬粉,优选地果蔬粉为草莓汁粉。
实施例2
本实施例提供一种抗幽益生菌组合物,包括1克益生菌粉A、1克益生菌粉B、1~2克菊粉和0.5~2克低聚果糖,所述益生菌粉A包含动物双歧杆菌,所述益生菌粉B包含罗伊氏乳杆菌,益生菌粉A和益生菌粉B的活菌数量均为50亿。该抗幽益生菌组合物还包括有50mg卵黄免疫球蛋白。该抗幽益生菌组合物为粉末状混合物。
作为保健品原料时,该抗幽益生菌组合物还包括0.5克果蔬粉,优选地果蔬粉为草莓汁粉。
实施例3
本实施例提供一种抗幽益生菌组合物,包括1.6克益生菌粉A、0.8克益生菌粉B、1~2克菊粉和0.5~2克低聚果糖,所述益生菌粉A包含动物双歧杆菌,所述益生菌粉B包含嗜酸乳杆菌,益生菌粉A的活菌数量为80亿,益生菌粉B的活菌数量为40亿。该抗幽益生菌组合物还包括有50mg蛋黄球蛋白粉。该抗幽益生菌组合物为粉末状混合物。
作为保健品原料时,该抗幽益生菌组合物还包括0.5克果蔬粉,优选地果蔬粉为草莓汁粉。
实施例4
本实施例提供一种抗幽益生菌组合物,包括1.6克益生菌粉A、0.8克益生菌粉B、1~2克菊粉和0.5~2克低聚果糖,所述益生菌粉A包含动物双歧杆菌,所述益生菌粉B包含罗伊氏乳杆菌,益生菌粉A的活菌数量为80亿,益生菌粉B的活菌数量为40亿。该抗幽益生菌组合物还包括有50mg卵黄免疫球蛋白。该抗幽益生菌组合物为粉末状混合物。
作为保健品原料时,该抗幽益生菌组合物还包括0.5克果蔬粉,优选地果蔬粉为木瓜粉。
实施例5
本实施例提供一种抗幽益生菌组合物,包括1.2克益生菌粉A、0.8克益生菌粉B、1~2克菊粉和0.5~2克低聚果糖,所述益生菌粉A包含动物双歧杆菌,所述益生菌粉B包含嗜酸乳杆菌,益生菌粉A的活菌数量为60亿,益生菌粉B的活菌数量为40亿。该抗幽益生菌组合物还包括有50mg蛋黄球蛋白粉。该抗幽益生菌组合物为粉末状混合物。
作为保健品原料时,该抗幽益生菌组合物还包括0.4克果蔬粉,优选地果蔬粉为草莓汁粉。
实施例6
本实施例提供一种抗幽益生菌组合物,包括1.2克益生菌粉A、0.8克益生菌粉B、1~2克菊粉和0.5~2克低聚果糖,所述益生菌粉A包含动物双歧杆菌,所述益生菌粉B包含罗伊氏乳杆菌,益生菌粉A的活菌数量为60亿,益生菌粉B的活菌数量为40亿。该抗幽益生菌组合物还包括有50mg蛋黄球蛋白粉。该抗幽益生菌组合物为粉末状混合物。
作为保健品原料时,该抗幽益生菌组合物还包括0.5克果蔬粉,优选地果蔬粉为草莓汁粉。
实施例7
本实施例提供一种抗幽益生菌组合物,包括2.4克益生菌粉A、0.8克益生菌粉B、1~2克菊粉和0.5~2克低聚果糖,所述益生菌粉A包含动物双歧杆菌,所述益生菌粉B包含嗜酸乳杆菌,益生菌粉A的活菌数量为120亿,益生菌粉B的活菌数量为40亿。该抗幽益生菌组合物还包括有50mg蛋黄球蛋白粉。该抗幽益生菌组合物为粉末状混合物。
作为保健品原料时,该抗幽益生菌组合物还包括0.4克果蔬粉,优选地果蔬粉为草莓汁粉。
实施例8
本实施例提供一种抗幽益生菌组合物,包括2.4克益生菌粉A、0.8克益生菌粉B、1~2克菊粉和0.5~2克低聚果糖,所述益生菌粉A包含动物双歧杆菌,所述益生菌粉B包含罗伊氏乳杆菌,益生菌粉A的活菌数量为120亿,益生菌粉B的活菌数量为40亿。该抗幽益生菌组合物还包括有50mg蛋黄球蛋白粉。该抗幽益生菌组合物为粉末状混合物。
作为保健品原料时,该抗幽益生菌组合物还包括0.5克果蔬粉,优选地果蔬粉为木瓜粉。
本发明实施例还公开了一种保健制品,包含所述的抗幽益生菌组合物。该保健制品可以是固体饮料、保健食品或保健饮品。
本发明实施例还公开了一种抗幽益生菌组合物的制造方法,用于制造所述的抗幽益生菌组合物,对辅料进行干燥处理,将益生菌粉A和益生菌粉B置于车间内回温4~8小时,在干燥后的辅料中加入益生菌粉A和益生菌粉B进行混合,车间温度为18~23摄氏度,车间的相对湿度低于30%。所述辅料包括菊粉、低聚果糖和果蔬粉。优选地,所述辅料干燥至水分活性值为2.0~2.5,然后对干燥后的辅料进行称重操作。益生菌粉A和益生菌粉B均为冻干粉。
在另一种实施方式中,先将辅料与蛋黄球蛋白粉或卵黄免疫球蛋白混合10分钟以上;再加入益生菌粉A和益生菌粉B进行混合30分钟以上。
以上示意性地对本发明及其实施方式进行了描述,该描述没有限制性。所以,如果本领域的普通技术人员受其启示,在不脱离本发明创造宗旨的情况下,不经创造性地设计出与该技术方案相似的结构方式及实施例,均应属于本发明的保护范围。
Claims (10)
1.抗幽益生菌组合物,其特征在于,包括益生菌粉A、益生菌粉B、菊粉和低聚果糖,所述益生菌粉A包含动物双歧杆菌,所述益生菌粉B包含嗜酸乳杆菌或罗伊氏乳杆菌,所述益生菌粉A和所述益生菌粉B的重量比为1~3:1。
2.根据权利要求1所述的抗幽益生菌组合物,所述益生菌粉A和所述益生菌粉B的活菌数量比为1~3:1。
3.根据权利要求1或2所述的抗幽益生菌组合物,还包括有蛋黄球蛋白粉或卵黄免疫球蛋白。
4.根据权利要求3所述的抗幽益生菌组合物,还包括果蔬粉,所述果蔬粉的重量大于所述蛋黄球蛋白粉或所述卵黄免疫球蛋白的重量。
5.根据权利要求4所述的抗幽益生菌组合物,所述蛋黄球蛋白粉或所述卵黄免疫球蛋白的重量大于或等于50mg。
6.根据权利要求5所述的抗幽益生菌组合物,所述抗幽益生菌组合物为粉末状混合物。
7.保健制品,其特征在于,包含如权利要求1-6任意一项所述的抗幽益生菌组合物。
8.抗幽益生菌组合物的制造方法,其特征在于,用于制造如权利要求1-6任一项所述的抗幽益生菌组合物,对辅料进行干燥处理,将益生菌粉A和益生菌粉B置于车间内回温4~8小时,在干燥后的辅料中加入益生菌粉A和益生菌粉B进行混合,车间温度为18~23摄氏度,车间的相对湿度低于30%。
9.根据权利要求8所述的抗幽益生菌组合物的制造方法,先将辅料与蛋黄球蛋白粉或卵黄免疫球蛋白混合10分钟以上;再加入益生菌粉A和益生菌粉B进行混合30分钟以上。
10.根据权利要求8或9所述的抗幽益生菌组合物的制造方法,所述辅料包括菊粉、低聚果糖和果蔬粉。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210270282.1A CN114642262A (zh) | 2022-03-18 | 2022-03-18 | 抗幽益生菌组合物及其制品和制造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210270282.1A CN114642262A (zh) | 2022-03-18 | 2022-03-18 | 抗幽益生菌组合物及其制品和制造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114642262A true CN114642262A (zh) | 2022-06-21 |
Family
ID=81994652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210270282.1A Pending CN114642262A (zh) | 2022-03-18 | 2022-03-18 | 抗幽益生菌组合物及其制品和制造方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114642262A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115997933A (zh) * | 2022-06-23 | 2023-04-25 | 苏州聚和堂生物科技有限公司 | 一种蛋黄球蛋白益生菌粉及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109464487A (zh) * | 2018-11-28 | 2019-03-15 | 吉林禾未来功能产品有限公司 | 抗幽门螺杆菌的益生菌复合物及其制备方法 |
CN112617080A (zh) * | 2020-12-30 | 2021-04-09 | 江苏协合转化医学研究院有限公司 | 一种蛋黄球蛋白益生菌直饮粉及其制备方法 |
CN112914103A (zh) * | 2021-02-22 | 2021-06-08 | 漯河微康生物科技有限公司 | 一种抗幽门螺杆菌感染的益生菌组合物及其应用 |
CN113559131A (zh) * | 2021-07-23 | 2021-10-29 | 科为博(江苏)生物科技研究院有限公司 | 一种用于改善肠胃的益生菌粉 |
-
2022
- 2022-03-18 CN CN202210270282.1A patent/CN114642262A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109464487A (zh) * | 2018-11-28 | 2019-03-15 | 吉林禾未来功能产品有限公司 | 抗幽门螺杆菌的益生菌复合物及其制备方法 |
CN112617080A (zh) * | 2020-12-30 | 2021-04-09 | 江苏协合转化医学研究院有限公司 | 一种蛋黄球蛋白益生菌直饮粉及其制备方法 |
CN112914103A (zh) * | 2021-02-22 | 2021-06-08 | 漯河微康生物科技有限公司 | 一种抗幽门螺杆菌感染的益生菌组合物及其应用 |
CN113559131A (zh) * | 2021-07-23 | 2021-10-29 | 科为博(江苏)生物科技研究院有限公司 | 一种用于改善肠胃的益生菌粉 |
Non-Patent Citations (1)
Title |
---|
程瑶等: "卵黄免疫球蛋白治疗幽门螺旋杆菌感染研究进展", 《海峡药学》, vol. 31, no. 11, pages 5 - 8 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115997933A (zh) * | 2022-06-23 | 2023-04-25 | 苏州聚和堂生物科技有限公司 | 一种蛋黄球蛋白益生菌粉及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kanamori et al. | Combination therapy with Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides dramatically improved the intestinal function in a girl with short bowel syndrome: a novel synbiotics therapy for intestinal failure | |
US20100166721A1 (en) | Probotic compositions and uses thereof | |
CN110051003A (zh) | 一种复合益生菌组合物及其应用 | |
US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
US20080102061A1 (en) | Use hydrolyzed medium containing microorganisms medicinally | |
CN101678054A (zh) | 在外科手术前和/或外科手术后环境中的益生菌 | |
CN105942505A (zh) | 一种五联益生菌营养粉配方及制备工艺 | |
Manigandan et al. | Probiotics, prebiotics and synbiotics-a review | |
KR101768678B1 (ko) | 한국 장수마을에서 개발된 건강기능성이 우수한 비피도박테리움 롱검 아종 인판티스 bi9988 | |
ES2716973T3 (es) | Lactobacillus rhamnosus RHT-3201 conjugado con aglutinante polimérico polisacárido y uso del mismo para la prevención o tratamiento de enfermedades atópicas | |
CN109430407A (zh) | 益生菌组合制剂 | |
Caramia et al. | Probiotics: from the ancient wisdom to the actual therapeutical and nutraceutical perspective | |
CN111671079A (zh) | 一种复合益生菌粉组合物及其制备方法 | |
ES2400187T3 (es) | Bacterias lácticas y su uso en la prevención de la diarrea | |
CN114642262A (zh) | 抗幽益生菌组合物及其制品和制造方法 | |
Onyenweaku et al. | Research Article Health Benefits of Probiotics | |
CN112971066A (zh) | 一种益生菌果泥 | |
TWI745454B (zh) | 抑制腸道內乳桿菌屬乳酸菌減少用之組成物 | |
CN114949202A (zh) | 一种益生菌和蛋白质的组合物及其抗幽门螺旋杆菌的应用 | |
KR101779719B1 (ko) | 신규한 락토바실러스 케피아노파시엔스 dn1 균주 및 이를 포함하는 변비의 예방 또는 치료용 조성물 | |
Pavithra et al. | Probiotics–A Miracle in Periodontal Therapy | |
KR102536139B1 (ko) | 락토바실러스 브레비스 ku15147을 포함하는 관절염 예방 또는 치료용 조성물 | |
ES2966935T3 (es) | Composiciones de lactobacillus plantarum y sus usos | |
WO2014163031A1 (ja) | 即効性の整腸剤 | |
CN113142586A (zh) | 一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |